CATALYST PHARMACEUTICALS, INC. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of cash flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Operating Activities:
Net income
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Depreciation
Stock-based compensation
Amortization of intangible assets
Deferred taxes
Accretion of discount
Reduction in the carrying amount of right-of-use asset
Realized loss on sale of available-for-sale securities
Acquired research and development inventory expensed from asset acquisition
Acquired inventory samples expensed from asset acquisition
Acquired in-process research and development
Change in fair value of equity securities
Inventory reserve and write-offs
(Increase) decrease in:
Accounts receivable, net
Inventory, net
Prepaid expenses and other current assets
Increase (decrease) in:
Accounts payable
Accrued expenses and other liabilities
Operating lease liability
Net cash provided by (used in) operating activities
Investing Activities:
Purchases of property and equipment
Purchases of investments
Proceeds from maturities and sales of investments
Proceeds from sale of available-for-sale securities
Payment in connection with license agreement
Payments in connection with asset acquisitions
Acquisition of in-process research and development
Purchase of equity securities
Net cash provided by (used in) investing activities

Financing Activities:
Payment of employee withholding tax related to stock-based compensation
Proceeds from exercise of stock options
Repurchase of common stock
Payment of liabilities arising from asset acquisition
Proceeds from issuance of common stock
Payment of fees in connection with issuance of common stock
Net cash provided by (used in) financing activities
Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents – beginning of period
Cash and cash equivalents – end of period
Supplemental disclosures of cash flow information:
Cash paid for income taxes
Cash paid for interest
Non-cash investing and financing activities:
Operating lease liabilities arising from obtaining right-of-use assets
Liabilities arising from asset acquisition
Accrued milestone payment classified as license and acquired intangibles, net

Comments